» Articles » PMID: 32662306

Emerging Medical Therapies in Crush Syndrome - Progress Report from Basic Sciences and Potential Future Avenues

Overview
Journal Ren Fail
Publisher Informa Healthcare
Date 2020 Jul 15
PMID 32662306
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Crush injury is a disease that is commonly found in victims of earthquakes, debris flows, mine disasters, explosions, terrorist attacks, local wars, and other accidents. The complications that arise due to the crush injury inflicted on victims give rise to crush syndrome (CS). If not treated in time, the mortality rate of CS is very high. The most important measure that can be taken to reduce mortality in such situations is to immediately start treatment. However, the traditional treatment methods such as fluid resuscitation, diuresis, and hemodialysis are not feasible enough to be carried out at the disaster scene. So there is a need for developing new treatments that are efficient and convenient. Because it is difficult to diagnose in the disaster area and reach the treatment equipment and treat on time. It has become a new research needs to be directed into identifying new medical treatment targets and methods using the etiology and pathophysiological mechanisms of CS. In recent years, a large number of new anti-oxidant and anti-inflammatory drug therapies have been shown to be highly efficacious in CS rat/mouse models. Some of them are expected to become specific drugs for the emergency treatment of a large number of patients who may develop CS in the aftermath of earthquakes, wars, and other disasters in the future. Hence, we have reviewed the latest research on the medical therapy of CS as a source for anyone wishing to pursue research in this direction.

Citing Articles

Mortality risk factors for crush syndrome after an earthquake in Türkiye: Do systemic inflammatory parameters play any role?.

Turktan M, Dogan O, Gok M, Aydin K, Gulec E, Hatipoglu Z Ulus Travma Acil Cerrahi Derg. 2024; 30(8):588-595.

PMID: 39092965 PMC: 11372493. DOI: 10.14744/tjtes.2024.09637.


The role of ferroptosis in acute kidney injury: mechanisms and potential therapeutic targets.

Yu Y, Zhang L, Zhang D, Dai Q, Hou M, Chen M Mol Cell Biochem. 2024; 480(2):759-784.

PMID: 38943027 DOI: 10.1007/s11010-024-05056-3.


Mini Review of Biochemical Basis, Diagnosis and Management of Crush Syndrome.

Hamlah A, Tarabishy A, Al-Madhagi H Acta Med Litu. 2024; 30(2):133-138.

PMID: 38516515 PMC: 10952423. DOI: 10.15388/Amed.2023.30.2.5.


The Evaluation of Different Treatment Approaches in Patients With Earthquake-Related Crush Syndrome.

Koyuncu S, Sipahioglu H, Bol O, Ilik H, Dilci A, Elmaagac M Cureus. 2023; 15(10):e47194.

PMID: 37854473 PMC: 10580897. DOI: 10.7759/cureus.47194.


Crush syndrome: a review for prehospital providers and emergency clinicians.

Usuda D, Shimozawa S, Takami H, Kako Y, Sakamoto T, Shimazaki J J Transl Med. 2023; 21(1):584.

PMID: 37653520 PMC: 10472640. DOI: 10.1186/s12967-023-04416-9.


References
1.
Yu J, Fan B, Guo J, Shen Y, Hu Y, Liu X . Anisodamine Ameliorates Hyperkalemia during Crush Syndrome through Estradiol-Induced Enhancement of Insulin Sensitivity. Front Pharmacol. 2019; 10:1444. PMC: 6902024. DOI: 10.3389/fphar.2019.01444. View

2.
Sharples E, Thiemermann C, Yaqoob M . Mechanisms of disease: Cell death in acute renal failure and emerging evidence for a protective role of erythropoietin. Nat Clin Pract Nephrol. 2006; 1(2):87-97. DOI: 10.1038/ncpneph0042. View

3.
Zhao C, Ron S, Liu C, He X, Xie Z . [Blocking effect of anisodamine on acetylcholine receptor channels]. Zhongguo Yao Li Xue Bao. 1993; 14(2):190-2. View

4.
Zhao T, Li D, Liu C, Su D, Shen F . Beneficial effects of anisodamine in shock involved cholinergic anti-inflammatory pathway. Front Pharmacol. 2011; 2:23. PMC: 3108475. DOI: 10.3389/fphar.2011.00023. View

5.
Homsi E, Machado de Brito S, Janino P . Silymarin exacerbates p53-mediated tubular apoptosis in glycerol-induced acute kidney injury in rats. Ren Fail. 2010; 32(5):623-32. DOI: 10.3109/08860221003778064. View